HealthcareServices

Axial Spondyloarthritis (axSpA) Market Report 2026: Strategic Insights and Revenue Outlook

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the axial spondyloarthritis (axspa) market from 2026–2035 with trusted insights from The Business Research Company

How is the Axial Spondyloarthritis (axSpA) Market size predicted to change over the forecast window of 2026–2035?

The axial spondyloarthritis (axspa) market has experienced robust growth over the past few years. This market is projected to expand from $6.56 billion in 2025 to $7.09 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. Historically, this expansion has been driven by factors such as heightened awareness of inflammatory spinal disorders, the broader application of TNF inhibitors, enhanced availability of diagnostic imaging, an increase in specialized rheumatology care, and initiatives promoting greater treatment adherence.

The market size for axial spondyloarthritis (axspa) is anticipated to experience substantial growth in the forthcoming years. It is projected to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period can be linked to the increasing adoption of JAK inhibitors and IL therapies, rising investments in personalized medicine, the broadening of early screening programs, a growing utilization of digital disease monitoring platforms, and ongoing innovation in biologic drug development. Key trends expected in the forecast period encompass a greater adoption of biologic therapies, an increased use of targeted anti-inflammatory drugs, an intensified focus on early diagnosis and disease monitoring, the expansion of personalized treatment approaches, and improved integration of digital health tools.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

Which Drivers Are Contributing To The Expansion Of The Axial Spondyloarthritis (axSpA) Market?

An expanding aging demographic is anticipated to stimulate the future expansion of the axial spondyloarthritis (axSpa) market. This demographic shift signifies a rising proportion or greater percentage of older individuals within a population. For the elderly, managing and treating axSpA offers advantages such as enhanced joint mobility and function, better quality of life, protection against spinal structural damage, lower healthcare expenditures, prevention of disabilities, and refined treatment approaches. As an illustration, Age UK, a UK-registered charity, reported that England had 11 million individuals over 65 in 2023. This figure is expected to rise by 10% over the subsequent five years and by 32% by 2043, representing 1.1 and 3.5 million people, respectively. Furthermore, the 85+ age group, which typically requires the most health and care services, is likewise forecast to experience rapid growth, with an increase of 8.2% in the next five years and 62.7% by 2043, corresponding to 126,000 and 956,000 people, respectively. Consequently, the expanding elderly population is a key factor fueling the development of the axial spondyloarthritis (axSpa) market.

What Segment Classifications Make Up The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

Which Market Trends Are Opening Growth Opportunities In The Axial Spondyloarthritis (axSpA) Market?

Leading companies in the axial spondyloarthritis (axSpA) market are focused on developing innovative solutions, such as next-generation biologic drug therapies, to satisfy the growing demand for effective treatments that target inflammation and improve long-term disease management. These biologic therapies work by modulating specific immune pathways, providing a more targeted method compared to traditional anti-inflammatory drugs, which primarily address symptoms without directly influencing the underlying immune drivers. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, secured approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is indicated for adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who show objective signs of inflammation, as indicated by elevated C-reactive protein. These European Union (EU) authorizations mark the drug’s initial global marketing licenses for axial spondyloarthritis.

Which Key Players Are Driving Competition In The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Region Is Projected To Lead The Axial Spondyloarthritis (axSpA) Market During The Forecast Period?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Axial Spondyloarthritis (axSpA) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795